Biological Psychiatry - Vol. 2

By Hugo D'Haenen; J.A. Den Boer et al. | Go to book overview

XXI-13
Therapeutic Armamentarium in Anxiety Disorders

J.A. den Boer, B.R. Slaap, G.J. ter Horst, T.I.F.H. Cremers and F.J. Bosker


INTRODUCTION

For decades benzodiazepines have been the mainstay in the treatment of anxiety disorders. It is only during the last decade mat tins situation has changed. With the introduction of serotonin reuptake inhibitors (SSRI's), 5-HT receptor-specific drugs like 5-HT1A agonists and recently, dual action antidepressants, new possibilities have been created for the treatment of panic disorder, obsessive compulsive disorder, social phobia, generalized anxiety disorder and post-traumatic stress disorder. In this chapter the pharmacotherapeutic options for the treatment of these anxiety disorders will be reviewed. We will focus on new developments and not reiterate all the studies performed with old tricyclic antidepressants (TCAs) such as imipramine, as these studies have been mentioned and reviewed in many other textbooks and papers.


PANIC DISORDER

Panic disorder (PD) is a chronic and recurring syndrome which requires long-term treatment. The disorder encompasses five essential domains: the panic attacks themselves, the associated anticipatory anxiety, phobic avoidance, and the resultant functional impairment and effects on quality of life. However, the complete resolution of panic attacks, the signal feature of panic disorder, is clearly important to patients. Modern studies on the efficacy in PD should measure symptoms domains outlined above (Shear and Maser, 1994).

Originally, tricyclic antidepressants (TCAs) like imipramine and clomipramine were the first found to be beneficial in panic disorder. Imipramine originally played a role in the sixties in the pharmacological dissection of panic and anxiety, as it was discovered that in patients suffering from anxiety neurosis, panic attacks disappeared during treatment with imipramine. The efficacy of imipramine has been the subject of many studies and this drug was used as a reference drug for years. TCAs, in spite of their proven efficacy, have many drawbacks, including high rates of non-compliance due to anticholinergic side-effects, weight gain, daytime sedation, orthostatic hypotension, lethality in overdose and withdrawal reactions (Wolfe, 1997; Bennett et al., 1998; den Boer, Bosker and Slaap, 2000). After six months treatment with imipramine dry mouth, constipation, sweating was still present as a substantial burden to patients (Mavissakalian and Perel, 2000). It is questionable whether by current standards, TCAs would be marketed if they were introduced today. Many studies have also been performed with BDZs in PD and there is a large database indicating that high potency BDZs such as clonazepam and alprazolam are efficacious in PD. Due to developments in psychopharmacology during the last decade it has, however, been questioned whether BDZs should be the first choice in the treatment of PD in view of their serious side-effects and withdrawal reactions.


Benzodiazepines in Panic Disorder

There are several placebo-controlled studies suggesting that clonazepam has therapeutic effects in PD. In one of the largest studies with clonazepam conducted so far, Rosenbaum and co-workers (1997) included 413 patients with PD in a fixed-dose placebocontrolled study in a 6-week study followed by a 7-week discontinuation phase. They used dosages ranging from 0.5 mg to 4.0 mg clonazepam daily and found that dosages of clonazepam of 1.0 mg were equally effective in reducing the number of panic attacks. During the discontinuation phase most patients worsened and reported increases in the number of panic attacks. Recently, Valenca et al. (2000) undertook a 6-week placebo-controlled study in 24 PD patients. They found that 11% of the placebo-treated patients were panic free after six weeks, whereas 62% of the clonazepam treated patients were panic free. Because treatment with BDZs has been associated with severe withdrawal reactions, Moroz and Rosenbaum (1999) treated PD patients with 0.25 up to 4.0 mg per day clonazepam for 6 weeks in a double-blind placebo controlled design, followed by a 7-week discontinuation phase during which the doses were gradually tapered. They observed no symptoms suggestive of withdrawal syndrome, nor evidence for rebound during the gradual tapering of clonazepam, but some patients did show worsening of symptomatology, most notably a recurrence of panic attacks. These data show that in the short-term clonazepam is efficacious but treatment in this study was probably too short to achieve full remission of panic attacks. On the other hand, a naturalistic follow-up study for 2 years in 204 patients showed that improvement in global severity of PD did not change during treatment with stable dosages of clonazepam, indicating that there was no development of tolerance (Worthington et al, 1998). In spite of the fact that clonazepam has been marketed in the US for PD, the two pivotal studies did not fulfil all the criteria that were set forth by Shear and Maser (1994), moreover, there is evidence that the higher dosages that are required in many patients are associated with withdrawal symptoms (Davidson et al, 1998).

Two large studies investigating the anxiolytic effects of alprazolam have been conducted in more than 1600 patients suffering from PD. The Cross-National Collaborative Panic Study and the Philadelphia study, which was a maintenance study (Ballenger et al., 1988; Noyes et al, 1988; Pecknold et al, 1988; Rickels et al, 1993; Schweizer et al., 1993). The results of these studies suggested that alprazolam was an effective drug in reducing the number of panic attacks. In spite of these results, these studies were criticized for several points; there was a very high placebo drop-out rate and the average dose was high (mean dose at week 8: 5.6 to 5.8 mg per day). These are important issues as even lower dosages have been shown to lead to impaired recall and other cognitive disturbances (Pomara et al., 1998). In addition, cessation of alprazolam treatment induces

-1039-

Notes for this page

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this book

This book has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this book

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this page

Cited page

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited page

Bookmark this page
Biological Psychiatry - Vol. 2
Table of contents

Table of contents

Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this book

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen
/ 730

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.